Efforts have been made to delay the acquired resistance to EGFR-TKI, such as adding chemotherapy to EGFR-TKI treatments (Cheng et al., 2016) or using osimertinib as the initial treatment for advanced NSCLC with sensitizing EGFR mutations (Ramalingam et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.